Research Progress of PARP Inhibitor Monotherapy and Combination Therapy for Endometrial Cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Endometrial cancer is a common gynecologic malignancy with poor outcomes for advanced or recurrent disease.
• Effective treatment strategies for advanced and recurrent endometrial cancer are limited.
• Homologous recombination repair (HRR) gene mutations are characteristic of endometrial cancer.

Purpose of the Study:

• To review the role of Poly (ADP-ribose) polymerase (PARP) inhibitors in treating endometrial cancer.
• To explore the efficacy of PARP inhibitors as monotherapy and in combination treatments.
• To identify ongoing clinical trials investigating PARP inhibitors for endometrial cancer.

Main Methods:

• Literature search of PubMed using keywords 'endometrial cancer' and 'PARP inhibitor'.
• Inclusion of specific PARP inhibitors (olaparib, rucaparib, niraparib, talazoparib) in clinicaltrials.gov search.
• Selection of English-language publications up to October 2020.

Main Results:

• PARP inhibitors selectively kill tumor cells with defects in homologous recombination repair.
• PARP inhibitors have demonstrated positive results in off-label treatments for endometrial cancer.
• Ongoing clinical trials are evaluating PARP inhibitors in monotherapy and combination settings.

Conclusions:

• PARP inhibitors are a significant therapeutic option for endometrial cancer, particularly those with HRR defects.
• Combination therapies involving PARP inhibitors with immune checkpoint inhibitors, PI3K/AKT/mTOR inhibitors, and cell cycle inhibitors show potential.
• Further research and clinical trials are warranted to optimize PARP inhibitor-based treatments for endometrial cancer.